Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Modeling Marginal Zone Lymphomagenesis

Victor Yazbeck, MD, Ian McConnell, Emily Harris, Joseph Lownik, Ariel Sindel, DO, Roy Sabo, PhD, Alden Chesney, MD, Guanhua Lai, MD PhD, Adolfo Mauro, PhD, Chad Cain, Fadi N. Salloum, Jamal Zweit, PhD, Steven Grant, MD, Jolene Windle, PhD, Steven Grossman, MD

Blood (2020) 136 (Supplement 1): 31.

https://doi.org/10.1182/blood-2020-142768

Published: 2020

Journal Articles

Role of the PI3K Pathway in the Pathogenesis of Marginal Zone Lymphoma

Ariel Sindel, DO, Ian McConnell, MS, Jolene Windle, PhD, Roy Sabo, PhD, Alden Chesney, MD, Guanhua Lai, MD PhD, Adolfo Mauro, PhD, Taha Al-Juhaishi, MD, Mohamed Rahmani, PhD, Jamal Zweit, PhD, Steven Grant, MD, Steven Grossman, MD, Victor Youssef Yazbeck, MD

Blood (2018) 132 (Supplement 1): 4125.

https://doi.org/10.1182/blood-2018-99-111284

Published: 2018

Journal Articles

Alvocidib Enhances Venetoclax Sensitivity in Unfavorable-Risk Multiple Myeloma Cells In Vitro and In Vivo

Liang Zhou, PhD, Yu Zhang, PhD, Deepak Sampath, PhD, Joel D. Leverson, PhD, Yun Dai, MD, Maciej Kmieciak, Matthew Nguyen, Robert Z. Orlowski, MD PhD, Steven Grant, MD

Blood (2017) 130 (Supplement 1): 2540.

https://doi.org/10.1182/blood.V130.Suppl_1.2540.2540

Published: 2017

Journal Articles

Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of Ikbα and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma

Joel G Turner, PhD, Trinayan Kashyap, MS, Jana L Dawson, BS, Juan A Gomez, BS, Alexis Bauer, BS, Steven Grant, MD, Yun Dai, PhD, Kenneth H. Shain, MD PhD, Mark B Meads, PhD, Yosef Landesman, PhD, Daniel M Sullivan, MD

Blood (2016) 128 (22): 3299.

https://doi.org/10.1182/blood.V128.22.3299.3299

Published: 2016

Journal Articles

Gls Inhibitor CB-839 Modulates Cellular Metabolism in AML and Potently Suppresses AML Cell Growth When Combined with 5-Azacitidine

Tianyu Cai, PhD, Philip L Lorenzi, PhD, Dinesh Rakheja, MD, Michael A Pontikos, Alessia Lodi, Lina Han, MD PhD, Qi Zhang, MD PhD, Helen Ma, MS, Mohamed Rahmani, PhD, Tushar Damodar Bhagat, PhD, Thomas D Horvath, PhD, Courtney D. DiNardo, MD MSCE, Steven Grant, MD, Stefano Tiziani, PhD, Amit Verma, MD, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 4064.

https://doi.org/10.1182/blood.V128.22.4064.4064

Published: 2016

Journal Articles

Combination Therapy of Selinexor with Bortezomib or Carfilzomib Overcomes Drug Resistance to Proteasome Inhibitors (PI) in Human Multiple Myeloma

Daniel M Sullivan, MD, Trinayan Kashyap, MS, Jana L Dawson, BS, Yosef Landesman, PhD, Steven Grant, MD, Kenneth H. Shain, MD PhD, Yun Dai, PhD, Michael Kauffman, MD PhD, Sharon Shacham, Joel G Turner, PhD

Blood (2015) 126 (23): 3048.

https://doi.org/10.1182/blood.V126.23.3048.3048

Published: 2015

Journal Articles

Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma

Joel G Turner, PhD, Jana L Dawson, BS, Christopher L Cubitt, PhD, Erkan Baluglo, PhD, Steven Grant, MD, Yun Dai, PhD, Kenneth H Shain, MD PhD, William S. Dalton, PhD MD, Sharon Shacham, William Senapedis, PhD, Daniel M Sullivan, MD

Blood (2015) 126 (23): 1818.

https://doi.org/10.1182/blood.V126.23.1818.1818

Published: 2015

Journal Articles

Co-Administration of the mTORC1/TORC2 Inhibitor INK128 and the Bcl-2/Bcl-Xl Antagonist ABT-737 Kills Human Myeloid Leukemia Cells through Mcl-1 Down-Regulation and AKT Inactivation

Mohamed Rahmani, PhD, Mandy Mayo Aust, Elisa Hawkins, Rebecca E Parker, Leonid Reshko, Masey Ross, MD, Maciej Kmieciak, PhD, Kathryn Ann Rizzo, DO, PhD, Catherine I Dumur, PhD, Andrea Ferreira-Gonzalez, PhD, Steven Grant, MD

Blood (2015) 126 (23): 3676.

https://doi.org/10.1182/blood.V126.23.3676.3676

Published: 2015

Journal Articles

Melphalan and XPO1 Inhibitor Combination Therapy for the Treatment of Multiple Myeloma

Joel G Turner, PhD, Jana L Dawson, BS, Steven Grant, MD, Kenneth H. Shain, MD PhD, Yun Dai, MD PhD, Chris Cubitt, PhD, Rachid Baz, MD, Taiga Nishihori, MD, Michael Kauffman, MD PhD, Sharon Shacham, PhD MBA, Daniel M Sullivan, MD

Blood (2014) 124 (21): 2084.

https://doi.org/10.1182/blood.V124.21.2084.2084

Published: 2014

Journal Articles

Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results

Beata Holkova, MD, Maciej Kmieciak, PhD, Prithviraj Bose, MD, Shuo Ma, MD PhD, Amy Kimball, MD PhD, Mary Beth Tombes, RN, Ellen Shrader, BS, Wen Wan, PhD, Caryn Weir-Wiggins, Elizabeth Stoddert, Amanda Garnett Singh, RN, BSN, April Dean, BS, Sarah Conine, PhD, Heidi Sankala, PhD, John D. Roberts, MD, Thomas C. Shea, MD, Steven Grant, MD

Blood (2014) 124 (21): 3050.

https://doi.org/10.1182/blood.V124.21.3050.3050

Published: 2014

Journal Articles

HDAC Inhibitors Reciprocally Interacts the Wee1 Inhibitor AZD1775 to Abrogate Both the G1/S and G2/M Checkpoints Via Chk1-Related cdc2/Cdk1 Threonine 14 Dephosphorylation in AML Cells

Yun Dai, MD PhD, Liang Zhou, MDPhD, Yu Zhang, PhD, Shuang Chen, MD PhD, Maciej Kmieciak, PhD, Yun Leng, MD, Lin Hui, MD, Steven Grant, MD

Blood (2014) 124 (21): 997.

https://doi.org/10.1182/blood.V124.21.997.997

Published: 2014

Journal Articles

Bcl-2 Antagonism Potentiates MEK1/2/Chk1 Inhibitor Lethality in Multiple Myeloma Cells Overexpressing Bcl-2 through a Stat3-Dependent Mechanism

Xin-Yan Pei, MD, Michael W Sanderson, BS, Leena E Youssefian, M.S, Jessica Felthousen, BS, Lora B Kramer, BS, Yun Dai, PhD, Steven Grant, MD

Blood (2014) 124 (21): 4763.

https://doi.org/10.1182/blood.V124.21.4763.4763

Published: 2014

Journal Articles

Phase I Trial Of Carfilzomib In Combination With Vorinostat (SAHA) In Patients With Relapsed/Refractory B-Cell Lymphomas

Beata Holkova, MD, Maciej Kmieciak, PhD, Prithviraj Bose, MD, Paul M. Barr, MD, Mary Beth Tombes, RN, Ellen Shrader, BS, Erin Cebula, MPH, CCRP, Emily Pierce, RN, CCRC, Megan M. Herr, BS, Heidi Sankala, PhD, Changyong Feng, PhD, Richard I Fisher, MD, Steven Grant, MD, Jonathan W. Friedberg, MD

Blood (2013) 122 (21): 4375.

https://doi.org/10.1182/blood.V122.21.4375.4375

Published: 2013

Journal Articles

Bim-Targeting Therapy Circumvents Adaptive Bortezomib-Resistance In Myeloma Through a Novel Cross-Link Between Autophagy and Apoptosis

Shuang Chen, MD/PhD, Yun Dai, MD, PhD, Yu Zhang, PhD, Liang Zhou, MD/PhD, Hui Lin, MD, Xin-Yan Pei, Robert Z. Orlowski, M.D., Ph.D., Steven Grant, MD

Blood (2013) 122 (21): 601.

https://doi.org/10.1182/blood.V122.21.601.601

Published: 2013

Journal Articles

Inhibition Of PI3K/mTOR By BEZ235 Dramatically Potentiates Panobinostat-Induced Lethality In Diffuse Large B-Cell Lymphoma Through Multiple Mechanisms

Mohamed Rahmani, Ph.D, Mandy Aust, MS, LaShanale Wallace, BS, Steven Grant, MD

Blood (2013) 122 (21): 817.

https://doi.org/10.1182/blood.V122.21.817.817

Published: 2013

Journal Articles

Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma

Beata Holkova, MD, Thomas C. Shea, MD, Prithviraj Bose, MD, Mary Beth Tombes, RN, Ellen Shrader, Wen Wan, PhD, Caryn Weir-Wiggins, Elizabeth Stoddert, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Steven Grant, MD

Blood (2012) 120 (21): 1794.

https://doi.org/10.1182/blood.V120.21.1794.1794

Published: 2012

Journal Articles

The Rheumatoid Arthritis Drug Auranofin Has Significant in Vitro Activity in MCL and DLCL and Is Synergistic with a Glutathione Depleting Agent

Jolanta Skalska, PhD, Michelle M. Kiebala, PhD, Shannon P. Hilchey, PhD, Yun Dai, MD, PhD, Steven Grant, MD, Paul S. Brookes, PhD, Derick R. Peterson, PhD, Sanjay B. Maggirwar, PhD, Steven H. Bernstein, MD

Blood (2012) 120 (21): 1658.

https://doi.org/10.1182/blood.V120.21.1658.1658

Published: 2012

Journal Articles

Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update

Beata Holkova, MD, Prithviraj Bose, MD, Mary Beth Tombes, RN, Ellen Shrader, Wen Wan, PhD, Caryn Weir-Wiggins, Elizabeth Stoddert, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Guillermo Garcia-Manero, MD, Steven Grant, MD

Blood (2012) 120 (21): 3588.

https://doi.org/10.1182/blood.V120.21.3588.3588

Published: 2012

Journal Articles

Fractal Organization of the Human T Cell Repertoire in Health and Following Stem Cell Transplantation

Jeremy Meier, Allison F Hazlett, MS, Kassi Avent, MS, Jennifer Berrie, Kyle Payne, David Hamm, MS, Cindy Desmarais, PhD, Catherine Sanders, PhD, Kevin T Hogan, PhD, Steven Grant, MD, Kellie J Archer, PhD, Masoud H Manjili, DVM, PhD, Catherine Roberts, PhD, Amir A Toor, MD

Blood (2012) 120 (21): 4193.

https://doi.org/10.1182/blood.V120.21.4193.4193

Published: 2012

Journal Articles

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib.

Beata Holkova, MD, Edward B. Perkins, MD, PhD, Prithviraj Bose, MD, Daniel M Sullivan, MD, Rachid Baz, MD, Mary Beth Tombes, RN, Ellen Shrader, Viswanathan Ramakrishnan, PhD, Wen Wan, PhD, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Steven Grant, MD

Blood (2012) 120 (21): 2959.

https://doi.org/10.1182/blood.V120.21.2959.2959

Published: 2012

NARROW

Modeling Marginal Zone Lymphomagenesis

Role of the PI3K Pathway in the Pathogenesis of Marginal Zone Lymphoma

Alvocidib Enhances Venetoclax Sensitivity in Unfavorable-Risk Multiple Myeloma Cells In Vitro and In Vivo

Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of Ikbα and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma

Gls Inhibitor CB-839 Modulates Cellular Metabolism in AML and Potently Suppresses AML Cell Growth When Combined with 5-Azacitidine

Combination Therapy of Selinexor with Bortezomib or Carfilzomib Overcomes Drug Resistance to Proteasome Inhibitors (PI) in Human Multiple Myeloma

Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma

Co-Administration of the mTORC1/TORC2 Inhibitor INK128 and the Bcl-2/Bcl-Xl Antagonist ABT-737 Kills Human Myeloid Leukemia Cells through Mcl-1 Down-Regulation and AKT Inactivation

Melphalan and XPO1 Inhibitor Combination Therapy for the Treatment of Multiple Myeloma

Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results

HDAC Inhibitors Reciprocally Interacts the Wee1 Inhibitor AZD1775 to Abrogate Both the G1/S and G2/M Checkpoints Via Chk1-Related cdc2/Cdk1 Threonine 14 Dephosphorylation in AML Cells

Bcl-2 Antagonism Potentiates MEK1/2/Chk1 Inhibitor Lethality in Multiple Myeloma Cells Overexpressing Bcl-2 through a Stat3-Dependent Mechanism

Phase I Trial Of Carfilzomib In Combination With Vorinostat (SAHA) In Patients With Relapsed/Refractory B-Cell Lymphomas

Bim-Targeting Therapy Circumvents Adaptive Bortezomib-Resistance In Myeloma Through a Novel Cross-Link Between Autophagy and Apoptosis

Inhibition Of PI3K/mTOR By BEZ235 Dramatically Potentiates Panobinostat-Induced Lethality In Diffuse Large B-Cell Lymphoma Through Multiple Mechanisms

Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma

The Rheumatoid Arthritis Drug Auranofin Has Significant in Vitro Activity in MCL and DLCL and Is Synergistic with a Glutathione Depleting Agent

Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update

Fractal Organization of the Human T Cell Repertoire in Health and Following Stem Cell Transplantation

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only